What does CUSIP 152309100 represent in this 13F holders report?

CUSIP 152309100 is the security identifier for CNTA - Centessa Pharmaceuticals plc - COMMON STOCK used to aggregate holder disclosures.

How many institutions held CNTA - Centessa Pharmaceuticals plc - COMMON STOCK in Q4 2023?

56 institutional investors reported CNTA - Centessa Pharmaceuticals plc - COMMON STOCK for Q4 2023. Use the holders table for investor-level position and value details.

Centessa Pharmaceuticals plc - COMMON STOCK (CNTA)

CUSIP: 152309100

Q4 2023 13F Holders as of 31 Dec 2023

Type / Class: Equity / COMMON STOCK
Shares outstanding: 90,440,627
Total 13F shares: 71,279,084
Share change: +1,638,421
Total reported value: $567,382,245
Put/Call ratio: 19%
Price per share: $7.96
Number of holders: 56
Value change: +$15,317,885
Number of buys: 28
Number of sells: 12

Quarterly Holders Quick Answers

What is CUSIP 152309100?
CUSIP 152309100 identifies CNTA - Centessa Pharmaceuticals plc - COMMON STOCK in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2024
Previous quarter: Q3 2023

Recent filing periods for CUSIP 152309100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of CNTA - Centessa Pharmaceuticals plc - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Medicxi Ventures Management (Jersey) Ltd	13F 3/4/5	Company · 10%+ Owner	22%	19,963,157	$129,161,626	—	30 Sep 2023	13F 3/4/5
GENERAL ATLANTIC, L.P.	13F	Individual	11%	9,681,818	$62,641,362	—	30 Sep 2023	13F
BVF INC/IL	13F	Company	10%	9,103,054	$58,896,759	—	30 Sep 2023	13F
EcoR1 Capital, LLC	13F	Company	6.2%	5,618,779	$36,353,500	—	30 Sep 2023	13F
Vida Ventures Advisors, LLC	13F	Company	4.3%	3,931,818	$25,438,862	—	30 Sep 2023	13F
OUP Management Co., LLC	13F	Company	3.2%	2,937,615	$19,006,369	—	30 Sep 2023	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	3.1%	2,830,500	$18,313,335	—	30 Sep 2023	13F
FMR LLC	13F	Company	3.1%	2,787,194	$18,033,145	—	30 Sep 2023	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	2.8%	2,549,134	$16,493,000	—	30 Sep 2023	13F
TCG Crossover Management, LLC	13F	Company	2.3%	2,040,816	$13,204,079	—	30 Sep 2023	13F
Point72 Asset Management, L.P.	13F	Company	2%	1,840,482	$11,907,919	—	30 Sep 2023	13F
David J. Grainger	3/4/5	Chief Innovation Officer	— class O/S missing	990,290	$7,882,708	—	31 Dec 2023	3/4/5
Affinity Asset Advisors, LLC	13F	Company	1.1%	1,018,091	$6,587,049	—	30 Sep 2023	13F
Antoine Yver	3/4/5	EVP & Chairman of Development	— class O/S missing	783,066	$6,233,205	—	01 Jun 2023	3/4/5
MORGAN STANLEY	13F	Company	1.1%	957,951	$6,197,943	—	30 Sep 2023	13F
FRANKLIN RESOURCES INC	13F	Company	0.92%	832,348	$5,385,292	—	30 Sep 2023	13F
Boxer Capital, LLC	13F	Company	0.85%	770,708	$4,986,481	—	30 Sep 2023	13F
Sio Capital Management, LLC	13F	Company	0.84%	756,891	$4,897,085	—	30 Sep 2023	13F
Kynam Capital Management, LP	13F	Company	0.81%	730,472	$4,726,154	—	30 Sep 2023	13F
Tanager Wealth Management LLP	13F	Company	0.77%	696,096	$4,503,741	—	30 Sep 2023	13F
AMERICAN CENTURY COMPANIES INC	13F	Company	0.77%	694,885	$4,495,904	—	30 Sep 2023	13F
Cormorant Asset Management, LP	13F	Company	0.62%	561,600	$3,633,552	—	30 Sep 2023	13F
Octagon Capital Advisors LP	13F	Company	0.53%	475,600	$3,077,132	—	30 Sep 2023	13F
Francesco de Rubertis	3/4/5	Director	— class O/S missing	281,162	$2,238,050	—	21 Mar 2022	3/4/5
PLATINUM INVESTMENT MANAGEMENT LTD	13F	Company	0.37%	337,544	$2,183,910	—	30 Sep 2023	13F
BlackRock Finance, Inc.	13F	Company	0.36%	325,843	$2,108,205	—	30 Sep 2023	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.36%	323,349	$2,092,068	—	30 Sep 2023	13F
Thomas Templeman	3/4/5	Chief Technology Officer	— class O/S missing	188,244	$1,498,422	—	31 Mar 2023	3/4/5
Woodline Partners LP	13F	Company	0.23%	210,204	$1,360,020	—	30 Sep 2023	13F
Javad Shahidi	3/4/5	Chief Medical Officer	— class O/S missing	158,932	$1,265,099	—	30 Sep 2022	3/4/5
TD ASSET MANAGEMENT INC	13F	Company	0.21%	186,310	$1,205,426	—	30 Sep 2023	13F
INDEX VENTURES LIFE VI (JERSEY) L.P.	3/4/5	10%+ Owner	— class O/S missing	149,421	$1,189,391	—	27 May 2021	3/4/5
Ensign Peak Advisors, Inc	13F	Company	0.14%	125,157	$809,766	—	30 Sep 2023	13F
Aaron Kantoff	3/4/5	Director	— class O/S missing	60,000	$477,600	—	18 Nov 2021	3/4/5
Marella Thorell	3/4/5	Chief Accounting Officer	— class O/S missing	53,101	$422,684	—	21 Mar 2022	3/4/5
MANUFACTURERS LIFE INSURANCE COMPANY, THE	13F	Company	0.07%	63,021	$407,746	—	30 Sep 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.06%	53,100	$344,000	—	30 Sep 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.06%	51,943	$336,071	—	30 Sep 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.04%	31,833	$205,959	—	30 Sep 2023	13F
Rathbones Group PLC	13F	Company	0.03%	31,300	$202,511	—	30 Sep 2023	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.01%	11,600	$75,052	—	30 Sep 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.01%	10,650	$68,906	—	30 Sep 2023	13F
JPMORGAN CHASE & CO	13F	Company	0.01%	10,101	$65,353	—	30 Sep 2023	13F
BARCLAYS PLC	13F	Company	0.01%	6,400	$41,408	—	30 Sep 2023	13F
Lombard Odier SCmA Compagnie	13F	Individual	0.01%	5,820	$37,655	—	30 Sep 2023	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	3,066	$19,837	—	30 Sep 2023	13F
CITADEL ADVISORS LLC	13F	Company	0%	3,019	$19,533	—	30 Sep 2023	13F
OSAIC HOLDINGS, INC.	13F	Company	0%	2,813	$18,195	—	30 Sep 2023	13F
UBS Group AG	13F	Company	0%	2,636	$17,055	—	30 Sep 2023	13F
China Universal Asset Management Co., Ltd.	13F	Company	0%	1,357	$8,780	—	30 Sep 2023	13F

Institutional Holders of Centessa Pharmaceuticals plc - COMMON STOCK (CNTA) as of Q4 2023

As of 31 Dec 2023, Centessa Pharmaceuticals plc - COMMON STOCK (CNTA) was held by 56 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 71,279,084 shares. The largest 10 holders included Medicxi Ventures Management (Jersey) Ltd, GENERAL ATLANTIC, L.P., BVF INC/IL, EcoR1 Capital, LLC, Vida Ventures Advisors, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, Octagon Capital Advisors LP, and TCG Crossover Management, LLC. This page lists 56 institutional shareholders reporting positions in this security for the Q4 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2023 vs Q3 2023 Across Filers

Q3 2023 holders

Q4 2023 holders

Holder diff

Investor	Q3 2023 Shares	Q4 2023 Shares	Share Diff	Share Chg %	Q3 2023 Value $	Q4 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.